Valens GroWorks Announces ISO 17025 Accreditation
Valens GroWorks Corp. (CSE: VGW) (the “Company” or “Valens”), a multi-licensed
vertically integrated provider of cannabis products and services utilizing proprietary extraction processes, is pleased
to announce that its wholly-owned subsidiary Supra THC Services has obtained ISO 17025 accreditation for cannabis
testing. It is the first Dealer’s License using cannabis as it’s matrix in Canada to achieve this accreditation.
ISO 17025 accreditation scope includes methods for cannabinoids, pesticides, toxic metals, terpenes and residual
solvents. The ISO 17025 standard, General requirements for the competence of testing and calibration laboratories,
has become the international reference for testing and calibration laboratories wanting to demonstrate their capacity
to deliver trusted results. The International Standard, published jointly by ISO (International Organization for
Standardization) and IEC (International Electrotechnical Commission), contains a set of requirements enabling
laboratories to improve their ability to produce consistently valid results, by specifying the general requirements for
the competence, impartiality and commitment to continuous improvement of the laboratory’s operations.
“I am very proud of our team. It is critical that all cannabis testing labs demonstrate that they can achieve similar
performance standards so that consumers can trust that products tested are safe. Transparency is essential in this
sector, and we are committed to help lead the way. Securing testing results from an ISO 17025 accredited laboratory
is the best way for producers to ensure that they are producing high-quality, safe products. I would like to see Health
Canada mandate that all licensed testing labs demonstrate that they can meet a similar standard.” commented Dr.
Rob O’Brien, Valens’ CSO.
About Valens GroWorks
Valens GroWorks Corp. is a vertically integrated provider of Canadian cannabis products developed from our
proprietary extraction techniques, with three wholly-owned subsidiaries located in and around Kelowna, BC.
Subsidiary Valens Agritech has initiated cannabis production, processing and sales under a Health Canada Dealer’s
Licence, which includes a supply agreement with Canopy Growth Corporation under their extensive CraftGrow
distribution network. Subsidiary Supra THC Services is a Health Canada licensed cannabis testing lab providing
sector-leading analytical services and has partnered with Thermo Fisher Scientific to develop a Centre of Excellence
in Plant Based Medicine Analytics. Subsidiary Valens Farms is in the process of becoming a purpose-built facility in
compliance with European Union (EU) Good Manufacturing Practice (GMP) standards, ensuring the product from this
facility can be exported anywhere in the world where Cannabis is nationally legal for medical or adult usage purposes.
Please visit http://valensgroworks.com, http://www.valensagritech.com and http://www.suprathc.ca for details.
For further information, please contact:
Notice Regarding Forward Looking Statements
This news release contains certain “forward-looking statements” within the meaning of such statements under
applicable securities law. Forward-looking statements are frequently characterized by words such as “anticipates”,
“plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed”,
“positioned” and other similar words, or statements that certain events or conditions “may” or “will” occur. These
statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections
contained in the forward-looking statements throughout this news release. Forward-looking statements are based on
the opinions and estimates of management at the date the statements are made and are subject to a variety of risks
and uncertainties and other factors that could cause actual events or results to differ materially from those projected
in the forward-looking statements. The Corporation is under no obligation, and expressly disclaims any intention or
obligation, to update or revise any forward-looking statements, whether as a result of new information, future events
or otherwise, except as expressly required by applicable law.
The CSE or other regulatory authority has not reviewed, approved or disapproved the contents of this press release.
We seek Safe Harbour.